biomarin

Biotech to break out, buy these names: Analyst – CNBC.com

While the stocks are not cheap, they’re not expensive, he added. What investors are paying for is high quality growth and high quality earnings.Read MoreCramer: Secret pattern to unlocking biotech richesIn fact, he thinks people have underappreciated biotech’s “fantastic” margins, noting that the companies now have 50 to 70 percent operating margins and “tons of real cash flow.””These are real¬†[…]